Latrice, a 48-year-old teacher from Atlanta, went in for a routine physical in early 2023. She felt fine. Her main concern was her weight, which had climbed to 218 pounds since her late thirties. Her doctor ordered a metabolic panel. Her liver enzymes came back elevated. An ultrasound confirmed fatty liver. A biopsy, which her gastroenterologist ordered because the enzyme levels were higher than expected, confirmed something more serious: metabolic-associated steatohepatitis, or MASH, with stage 2 fibrosis.
“I didn’t even know this disease existed,” Latrice said. “I thought fatty liver was something that happened to people who drank heavily. I barely drink at all.”
She was right that alcohol is one cause. She was not alone in the confusion. Metabolic fatty liver disease is one of the most underdiagnosed serious conditions in American medicine, affecting an estimated 5 to 6 percent of U.S. adults in its progressive form. Until recently, physicians had almost nothing pharmacological to offer.
That has now changed.
What MASH Is and Why It Matters
MASLD, or metabolic dysfunction-associated steatotic liver disease, is the new clinical term for what was previously called nonalcoholic fatty liver disease (NAFLD). It describes a spectrum. Simple fat accumulation in the liver (steatosis) is common and often benign. When that fat triggers inflammation and cell death, it becomes MASH, the condition formerly called NASH (nonalcoholic steatohepatitis). When inflammation persists, fibrosis follows. Fibrosis progresses to cirrhosis. Cirrhosis can progress to liver failure or hepatocellular carcinoma.
Obesity and insulin resistance are the dominant drivers. An estimated 38 percent of adults in the United States have MASLD in some form. Approximately 5 to 6 percent have progressed to MASH with significant fibrosis, the stage where disease progression becomes a real clinical risk¹.
Until 2024, there were no FDA-approved medications specifically for MASH. Physicians told patients to lose weight. Some did. Most could not sustain enough loss for long enough to reverse hepatic inflammation.
GLP-1 medications changed that calculus.
The ESSENCE Trial
The ESSENCE trial was a Phase 3, randomized, placebo-controlled study of semaglutide 2.4 mg weekly in adults with biopsy-confirmed MASH and significant liver fibrosis (stages F2 or F3). Results were published in the New England Journal of Medicine on April 30, 2025, following headline data presented at AASLD in November 2024.
The trial enrolled approximately 1,200 patients randomized 2:1 to semaglutide or placebo. Participants received semaglutide 2.4 mg once weekly or placebo for 72 weeks.
The co-primary endpoints were:
- MASH resolution without worsening of fibrosis
- Fibrosis improvement of at least one stage without worsening of MASH activity
Results:
| Outcome | Semaglutide | Placebo |
| MASH resolution (no fibrosis worsening) | 62.9% | 34.3% |
| Fibrosis improvement ≥1 stage (no MASH worsening) | 36.8% | 22.4% |
| Both endpoints met | Yes (p less than 0.001 for each) | Reference |
Nearly two-thirds of semaglutide-treated patients achieved MASH resolution, compared to one-third of placebo patients. Fibrosis improvement was also significantly greater in the treatment group².
Weight loss in the semaglutide arm was approximately 10 to 11 percent of body weight over the trial period, consistent with prior studies at this dose range. Importantly, while weight loss likely contributed to liver improvement, analyses suggested the magnitude of hepatic response may exceed what weight loss alone would predict, a pattern consistent with direct GLP-1 receptor effects in hepatic tissue.
How GLP-1 Affects the Liver
GLP-1 receptors are expressed in the liver, though at lower density than in the pancreas or gut. The hepatic effects of GLP-1 therapy are likely multifactorial.
Fat reduction and lipotoxicity. The primary injury in MASH is lipotoxicity: fat accumulates in hepatocytes, generating oxidative stress and triggering inflammation. GLP-1 therapy reduces hepatic fat through several mechanisms: it decreases dietary calorie intake, reduces de novo lipogenesis (the liver’s production of new fat from carbohydrates), and improves insulin sensitivity, which reduces the flow of free fatty acids into the liver from peripheral fat stores³.
Inflammation suppression. GLP-1 receptor activation inhibits the NF-kB inflammatory pathway in hepatocytes and Kupffer cells (liver macrophages). This direct anti-inflammatory action may contribute to MASH resolution beyond what weight loss alone achieves. In pre-clinical models, GLP-1 receptor agonism reduced hepatic TNF-alpha and IL-6, the cytokines most directly implicated in hepatocyte injury and stellate cell activation.
Fibrosis biology. Hepatic stellate cells are the primary fibrosis-producing cells in the liver. Chronic inflammation activates them, causing collagen deposition. GLP-1 receptor activation has demonstrated anti-fibrotic effects in animal models, partly through direct stellate cell suppression and partly through reducing the upstream inflammatory signal that activates them. Whether this translates fully to human fibrosis reversal is an active area of ongoing investigation⁴.
The FDA Landscape for MASH Treatment
The ESSENCE data follows a pivotal year for MASH pharmacology.
In March 2024, the FDA approved resmetirom (Rezdiffra), a thyroid hormone receptor beta agonist, as the first drug specifically approved for MASH with moderate-to-advanced fibrosis. Resmetirom acts directly on liver metabolism through a different mechanism than GLP-1.
Semaglutide’s FDA approval specifically for MASH has not yet been granted as of the time of this writing. Novo Nordisk has submitted for approval based on ESSENCE data, and a decision is expected. If approved, semaglutide would become the second drug approved for MASH and the first approved agent with cardiovascular, metabolic, and hepatic indications simultaneously.
For patients who have both obesity and MASH, a physician prescribing semaglutide would be treating multiple conditions through one mechanism. That is clinically significant in a population that frequently carries three or four comorbidities simultaneously.
How MASH Is Diagnosed and Why Many Cases Are Missed
Fatty liver disease is largely asymptomatic until late stages. Most patients with MASH have no symptoms at all. The first sign is often an elevated ALT or AST on routine bloodwork. From there, diagnosis requires imaging and often biopsy.
Elevated liver enzymes on a metabolic panel are the most common initial finding. Levels do not need to be dramatically elevated; even modestly abnormal ALT in someone with obesity warrants follow-up.
Ultrasound detects hepatic steatosis reliably but cannot stage fibrosis.
FibroScan (transient elastography) measures liver stiffness non-invasively and provides a fibrosis estimate without biopsy. It has become the preferred next step after ultrasound in most gastroenterology practices.
Liver biopsy remains the gold standard for MASH diagnosis and staging. It is usually reserved for cases where non-invasive testing is ambiguous or where the degree of fibrosis will change clinical decisions.
Latrice’s case is common. Routine bloodwork caught it before she had symptoms. Many patients with MASH are never tested until a complication arises.
What This Means If You Have MASLD or MASH
If you have been told you have fatty liver, steatosis, elevated liver enzymes without explanation, or any of these findings in the context of overweight or obesity, a conversation with a gastroenterologist is warranted. Many primary care offices do not have specific protocols for MASLD follow-up. A specialist can stage your disease accurately and determine whether the progression risk warrants pharmacological treatment.
If you are already on semaglutide or tirzepatide for weight loss or metabolic reasons and also have diagnosed MASH or MASLD, ask your gastroenterologist whether your GLP-1 therapy may be treating both conditions and discuss monitoring your liver biomarkers over time.
GLP-1 therapy is not a substitute for diagnosing and staging hepatic disease correctly. Weight loss alone does not reverse advanced fibrosis reliably, and patients with cirrhosis require specialist management regardless of GLP-1 use.
Key Takeaway
The ESSENCE Phase 3 trial published in the New England Journal of Medicine found that semaglutide 2.4 mg produced MASH resolution in 62.9% of treated patients versus 34.3% with placebo, and fibrosis improvement of at least one stage in 36.8% versus 22.4%. These results represent the strongest pharmacological evidence yet for hepatic benefit in MASH. The mechanism combines metabolic improvement through weight loss with likely direct GLP-1 receptor anti-inflammatory and anti-fibrotic effects in liver tissue. FDA approval for this indication is under review. For the approximately 5 to 6 percent of American adults with MASH, this is one of the most significant treatment developments in liver medicine in decades.
Category
GLP-1, Semaglutide, Fatty Liver Disease, MASH, MASLD, NASH, NAFLD, ESSENCE Trial, Obesity, Metabolic Health, Liver Disease, Fibrosis
References
¹ Rinella ME, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023. Prevalence estimates and staging criteria.
² Sanyal AJ, et al. Semaglutide 2.4 mg in Patients with Metabolic-Associated Steatohepatitis (ESSENCE): A Randomized, Controlled Trial. New England Journal of Medicine. April 30, 2025.
³ GLP-1 receptor agonists and hepatic lipid metabolism: de novo lipogenesis inhibition, free fatty acid flux reduction, and insulin sensitization in liver tissue. Journal of Hepatology. 2023.
⁴ GLP-1 receptor activation and hepatic stellate cell biology: anti-fibrotic mechanisms in pre-clinical and early translational models. Hepatology. 2024.
⁵ FDA approves resmetirom (Rezdiffra) for metabolic-associated steatohepatitis with moderate-to-advanced fibrosis. FDA Press Release. March 2024.
Disclaimer
This article is for educational purposes only and is not medical advice. MASH is a serious liver disease requiring diagnosis and management by a qualified gastroenterologist or hepatologist. Elevated liver enzymes should be evaluated by your healthcare provider. Semaglutide does not yet carry an FDA-approved indication specifically for MASH as of the time of publication; this is under regulatory review. Do not start, stop, or modify any medication for liver disease without consulting your prescribing physician. Resmetirom (Rezdiffra) is the only currently FDA-approved pharmacological treatment specifically for MASH with moderate-to-advanced fibrosis.
